Two Biologics Work Equally Well for Active Crohn's Disease

For adults with moderate to severe Crohn's disease who have never been on a biologic agent, treatment with monotherapy with adalimumab or ustekinumab appear to be equally effective, according to results of the head-to-head SEAVUE trial.
Reuters Health Information

source https://www.medscape.com/viewarticle/975660?src=rss

Comments

Popular posts from this blog

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?